|
Name |
7-Dehydrobrefeldin A
|
Molecular Formula | C16H22O4 | |
IUPAC Name* |
(1R,2R,3E,7S,11E,13S)-2-hydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-diene-5,15-dione
|
|
SMILES |
C[C@H]1CCC/C=C/[C@@H]2CC(=O)C[C@H]2[C@@H](/C=C/C(=O)O1)O
|
|
InChI |
InChI=1S/C16H22O4/c1-11-5-3-2-4-6-12-9-13(17)10-14(12)15(18)7-8-16(19)20-11/h4,6-8,11-12,14-15,18H,2-3,5,9-10H2,1H3/b6-4+,8-7+/t11-,12+,14+,15+/m0/s1
|
|
InChIKey |
IKUWMGOXYQGWPC-TWAINWRDSA-N
|
|
Synonyms |
7-Dehydrobrefeldin A; 62989-90-6; (1R,2R,3E,7S,11E,13S)-2-hydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-diene-5,15-dione; 7-Oxo-bfa; 7-oxobrefeldin A; 13-keto-brefeldin A; 4H-Cyclopent(f)oxacyclotridecin-4,13(1H)-dione, 6,7,8,9,11a,12,14,14a-octahydro-1-hydroxy-6-methyl-, (1R-(1R*,2E,6S*,10E,11aS*,14aR*))-
|
|
CAS | 62989-90-6 | |
PubChem CID | 6441091 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 278.34 | ALogp: | 1.6 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 63.6 | Aromatic Rings: | 2 |
Heavy Atoms: | 20 | QED Weighted: | 0.546 |
Caco-2 Permeability: | -4.497 | MDCK Permeability: | 0.00002190 |
Pgp-inhibitor: | 0.763 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.056 |
Blood-Brain-Barrier Penetration (BBB): | 0.883 | Plasma Protein Binding (PPB): | 45.27% |
Volume Distribution (VD): | 0.45 | Fu: | 52.09% |
CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.108 |
CYP2C19-inhibitor: | 0.023 | CYP2C19-substrate: | 0.098 |
CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.868 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.57 |
CYP3A4-inhibitor: | 0.216 | CYP3A4-substrate: | 0.23 |
Clearance (CL): | 16.566 | Half-life (T1/2): | 0.883 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.099 |
Drug-inuced Liver Injury (DILI): | 0.172 | AMES Toxicity: | 0.041 |
Rat Oral Acute Toxicity: | 0.044 | Maximum Recommended Daily Dose: | 0.895 |
Skin Sensitization: | 0.311 | Carcinogencity: | 0.745 |
Eye Corrosion: | 0.925 | Eye Irritation: | 0.321 |
Respiratory Toxicity: | 0.04 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003460 | 0.672 | D0K7LU | 0.235 | ||||
ENC002215 | 0.672 | D0WE3O | 0.234 | ||||
ENC005098 | 0.672 | D0D2VS | 0.232 | ||||
ENC003784 | 0.672 | D0C7JF | 0.229 | ||||
ENC004599 | 0.623 | D03DIG | 0.227 | ||||
ENC004602 | 0.623 | D0D1SG | 0.221 | ||||
ENC004603 | 0.583 | D0I5DS | 0.217 | ||||
ENC001867 | 0.557 | D08PIQ | 0.217 | ||||
ENC003403 | 0.557 | D0D2TN | 0.217 | ||||
ENC005407 | 0.514 | D06WTZ | 0.214 |